An agreement is signed by HKBU, CUHK and PuraPharm Corporation Ltd to mark their collaboration in the first new Chinese medicine project with an integrative medical research approach in Hong Kong


浸大、中大與培力控股簽署合作協議,開展全港首個中西醫結合的科研協作成果

Date: 15 Nov 2016 (Tuesday)

Archive

HKBU joins CUHK and PuraPharm to develop new drugs for treating functional gastrointestinal disorders

浸大夥中大與業界研發新藥治療功能性腸胃病

The University signed a cooperation agreement with The Chinese University of Hong Kong (CUHK) and PuraPharm Corporation Ltd (PuraPharm) last Thursday (10 November) to develop new drugs for treating functional gastrointestinal disorders. The collaboration is the first new Chinese medicine project in Hong Kong with an integrative medical research approach. Based on the two universities’ research into irritable bowel syndrome – diarrhoea type (IBS-D) – and their profound knowledge of Chinese medicine, a treatment called Ren Shu Chang Le Granules was developed using technology provided by the manufacturer. 

IBS is a gastrointestinal disorder whose patients suffer from bowel dysfunction, gastric disorder or intestinal hypersensitivity, all of which affect their daily lives. It is estimated that 10-20% of people globally suffer from IBS with approximately 310,000 patients in Hong Kong. At present, treatment of IBS focuses on the relief of symptoms and on lifestyle changes. However such treatment has proved unsatisfactory. 

With the support of the Innovation and Technology Commission, the School of Chinese Medicine of HKBU together with the Faculty of Medicine of CUHK explored how to treat IBS with Chinese medicines in 2002. The research team of the two universities took reference from the traditional Chinese “diarrhoea formula” and revised it into a new formula for treating IBS-D. The prescription includes Chinese herbal medicines found only in the Ling Nan area (such as in Hong Kong).

The new drug is the first Hong Kong research project to be approved for clinical trial by the China Food and Drug Administration for treatment of functional gastrointestinal disorders. The first clinical trial for “Ren Shu Chang Le Granules” will start in 2017 and the treatment is scheduled to be registered as a new drug in 2020-2021. It is hoped that the drug will provide a new treatment for IBS patients in the Greater China region as well as for the entire world.

大學於上周四 (11月10日) 與香港中文大學和培力控股簽署合作協議,合力研發治療功能性腸胃病的新藥,是全港首個中西醫結合的科研協作成果。項目結合了兩所大學在治療腸易激綜合症──腹瀉類別上的研究知識和臨床所得,透過中藥企業的研發技術,成功將複方湯劑轉化成中藥顆粒「仁朮腸樂顆粒」,可望有效治療功能性腸胃病。

腸易激綜合症是功能性腸胃病的一種,患者會出現腸臟功能紊亂、失調或腸道過敏所引起的症狀,影響日常生活。全球估計約有10%至20%人士為腸易激綜合症患者,而香港亦有約31萬人士受該病症所困擾。現時,醫生主要是透過緩和患者的病徵及調節生活習慣來治療此症,但療效並不理想。

在創新科技署的支持下,浸大中醫藥學院與中大醫學院於2002年起開始進行研究,探索以中藥治療腸易激綜合症的可行性。兩所院校的中西藥科研團隊先參考中醫的傳統方劑「痛瀉要方」,並修訂成一道用於治療腸易激綜合症──腹瀉類別的藥方,藥方中包括嶺南地區 (如香港) 專屬的中草藥。

是次的科研成果是全港首個獲得國家食品藥品監督管理局批准於國內腸易激綜合症臨床研究的科研項目。新研發的中藥顆粒預計於明年可在內地開展臨床研究,並於未來四至五年內註冊,為大中華區以至全球的腸易激綜合症──腹瀉性患者提供新的治療選擇。